## Youngchul Kim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3499986/publications.pdf

Version: 2024-02-01

1307594 996975 16 241 7 15 citations g-index h-index papers 16 16 16 573 docs citations times ranked citing authors all docs

#	Article	lF	CITATIONS
1	Multi-Gene Expression Predictors of Single Drug Responses to Adjuvant Chemotherapy in Ovarian Carcinoma: Predicting Platinum Resistance. PLoS ONE, 2012, 7, e30550.	2.5	95
2	Investigating multi-radiomic models for enhancing prediction power of cervical cancer treatment outcomes. Physica Medica, 2018, 46, 180-188.	0.7	34
3	A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy. PLoS ONE, 2012, 7, e49529.	2.5	20
4	Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer, 2018, 18, 843.	2.6	16
5	PDXGEM: patient-derived tumor xenograft-based gene expression model for predicting clinical response to anticancer therapy in cancer patients. BMC Bioinformatics, 2020, 21, 288.	2.6	13
6	Retrospective Analysis of Survival Improvement by Molecular Biomarker-Based Personalized Chemotherapy for Recurrent Ovarian Cancer. PLoS ONE, 2014, 9, e86532.	2.5	13
7	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. Cancer Research, 2022, 82, 929-942.	0.9	13
8	Proteogenomic, Epigenetic, and Clinical Implications of Recurrent Aberrant Splice Variants in Clear Cell Renal Cell Carcinoma. European Urology, 2022, 82, 354-362.	1.9	13
9	A Randomized Clinical Trial of Precision Prevention Materials Incorporating <i>MC1R </i> Genetic Risk to Improve Skin Cancer Prevention Activities Among Hispanics. Cancer Research Communications, 2022, 2, 28-38.	1.7	9
10	CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget, 2018, 9, 1091-1106.	1.8	5
11	Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. European Urology Focus, 2021, 7, 373-380.	3.1	4
12	Assessment of melanoma precision prevention materials incorporating <i>MC1R</i> genetic risk information. Translational Behavioral Medicine, 2022, 12, 683-687.	2.4	3
13	Double error shrinkage method for identifying protein binding sites observed by tiling arrays with limited replication. Bioinformatics, 2009, 25, 2486-2491.	4.1	1
14	Retention and Evaluation of Precision and Generic Prevention Materials for Melanoma: A Qualitative Study Comparing Young Adults and Adults. Cancer Prevention Research, 2022, 15, 533-542.	1.5	1
15	Assessment of skin cancer precision prevention materials among Hispanics in Florida and Puerto Rico. Patient Education and Counseling, 2022, 105, 3143-3150.	2.2	1
16	Point success rate for patient therapeutic response prediction by continuous biomarker scores. Statistical Methods in Medical Research, 2016, 25, 1638-1647.	1.5	0